Biosimilars name, notification debates rage on in the US, but costs still 'elephant in the room'
This article was originally published in SRA
Executive Summary
Whatever the ultimate outcome turns out to be for the debates in the US over the naming of biosimilars or prescriber notification of interchangeable products, the medicines are bound to be "among the most deeply analyzed and predictable" drugs to hit the US market, said Dr Emily Shacter, a former Food and Drug Administration official and now an independent consultant with ThinkFDA.
You may also be interested in...
FDA And FTC Join Forces On Biosimilars
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
FDA, FTC Join Forces To Eliminate Barriers To Biosimilar Competition
Two agencies to take action against false or misleading communications about biosimilars, impediments to sampling, and anticompetitive patent settlement agreements; to hold public workshop in March.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.